All In Biotech

Drug Trial Radar · NCT03476681

Study of NEO-201 in Solid Tumors Expansion Cohorts

Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

121

Planned (sponsor's estimate)

Start

Jan 18, 2019

Primary completion

Jun 17, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
Precision Biologics, IncIndustry
Sponsor type
Industry
First posted
Mar 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The open label, first-in-human, phase 1, dose escalation component in refractory solid tumors has been completed. The Maximum Tolerated Dose and Recommended Phase 2 Dose (RP2D) was determined to be 1.5mg/kg. The Expansion Phase of this study is currently enrolling subjects with non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), cervical and uterine cancers who progressed on front line therapy. Subjects will be treated with NEO-201 at the RP2D (1.5 mg/kg) every 2 weeks in combination with pembrolizumab, given 1 day after the NEO-201, at 400 mg IV every 6 weeks.

Conditions

  • Non Small Cell Lung Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Cervical Cancer
  • Uterine Cancer

Interventions

  • NEO-201 in combination with pembrolizumabDrug

    NEO-201 will be given intravenously every 2 weeks in combination with pembrolizumab. In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the safety of the combination of NEO-201 with pembrolizumab the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.Time frame: 1.5 years
  2. Determine Objective Response Rate (either Complete Response or Partial Response) as determined by RECIST v1.1 guidelinesTime frame: 1.5 years
  3. Determine Progression Free Survival as determined by RECIST v1.1 guidelinesTime frame: 1.5 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Institute

    Bethesda, Maryland

  • INOVA Schar Cancer Institute

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.